Biogen Inc. (BIIB) Earnings Call Analysis

NASDAQ · Healthcare · Drug Manufacturers - General

Earnings Reports

• Biogen (BIIB) Q2 2026: Growth Portfolio Surges 24% as Appellis Integration Reshapes Revenue Trajectory
  July 29, 2026
• Biogen (BIIB) Q1 2026: Growth Portfolio Up 12% as Appellis Acquisition Sets EPS Inflection
  June 17, 2026
• Biogen (BIIB) Q3 2025: Launch Portfolio Soars 67%, Offsetting MS Erosion and Funding Pipeline Expansion
  June 16, 2026
• Biogen (BIIB) Q2 2025: Launch Product Revenue Jumps 91% as Pipeline and Commercial Engines Accelerate
  July 31, 2025
• Biogen (BIIB) Q1 2025: New Launches Drive 22% Sequential Growth as MS Headwinds Deepen
  July 04, 2025
• Biogen (BIIB) Q3 2024: Pipeline Peak Sales Targeted at $14B, Offsetting 3% Core Pharma Decline
  October 30, 2024
• Biogen (BIIB) Q2 2024: Core Pharma Grows 5% as New Launches Offset MS Decline
  August 01, 2024
• Biogen (BIIB) Q1 2024: New Launches Offset 4% MS Decline, Field Force Expands 30%
  April 24, 2024
• Biogen (BIIB) Q4 2023: $800M Cost Reset Targets, New Launches Offset 6% Legacy Slide
  February 13, 2024

Browse all companies